Lumenis Be has launched the first dual frequency radiofrequency (RF) device, OptiPLUS, in the U.S. market making the announcement during the American Academy of Ophthalmology (AAO) annual meeting.
Let’s start with this company.
Headquartered in Israel, Lumenis is an energy-based medical device company developing minimally-invasive clinical solutions for the surgical, ophthalmic, and aesthetic markets.
In the ophthalmic space, the company’s technologies are geared toward the following disease states:
Anything else to know?
First and foremost, you’ll need to know that the OptiPLUS is intended to be a complementary device to Lumenis’ novel OptiLIGHT technology—the first and only intense pulsed light (IPL) therapy FDA-approved for the management of dry eye disease (DED) due to meibomian gland dysfunction (MGD).
OptiLIGHT utilizes the company’s patented Optimal Pulse Technology (OPT), which can give users the ability to control pulse shape, present reproducible results, as well as provide enhanced comfort during treatment.
Gotcha. Now talk about OptiPLUS.
Per Lumenis, the RF device is designed to deliver heat across tissue layers, leading to a potential increase in blood circulation with the goal to improve medical performance and aesthetic results.
Explain how it works.
The OptiPLUS’ RF frequency technology enables the device to use energy penetration at different skin depths, “heating the superficial layer to promote collagen formation and stimulate periorbital skin rejuvenation,” according to Lumenis. At the same time, this energy targets the meibomian glands by reaching into deeper tissue
How is patient comfort taken into consideration?
Via a “unique monopolar application,” the device has been designed to ensure optimized contact with the periorbital area’s delicate contours—all to provide additional patient safety and comfort.
The company also stated that the technology’s pre-embedded settings and temperature control have been engineered with the intention to improve efficacy and safety.
How does it differ from OptiLIGHT?
One significant distinction: OptiLIGHT depends on the light-based OPT to treat dry eye inflammation (due to MGD), whereas the OptiPLUS device uses RF energy to achieve its clinical outcome for DED.
Any clinical data on it?
Yes, actually. Recent research published last month in Clinical Ophthalmology evaluated the pairing of the OptiLIGHT and OptiPLUS technologies which demonstrated, “significantly improving the number of expressible meibomian glands (over 150% average), meibum clarity (over 70%) and symptoms (over 60%),” according to lead investigator James Chelnis, MD, FACS.
So… where can I demo this?
If you’re still at AAO today, check it out at the Lumenis booth (#1039).
And if not, click here to learn more about OptiPLUS and OptiLIGHT.
The American Academy of Ophthalmology (AAO) annual meeting is being held Nov. 3-6, 2023, in San Francisco, California.